| Business Summary | | The
Quigley
Corporation's
primary
business
is
the
manufacture
and
distribution
of
cold
remedy
products
to
the
consumer
through
the
over-the-counter
marketplace.
Its
key
product,
Cold-Eeze,
is
a
zinc
gluconate
glycine
lozenge,
which,
in
two
double-blind
clinical
studies,
reduced
the
duration
and
severity
of
the
common
cold
symptoms.
Since
its
inception,
the
Company
has
continued
to
conduct
research
and
development
into
various
types
of
health-related
food
supplements
and
homeopathic
cold
remedies.
In
January
2000,
Darius
International,
Inc.
a
wholly
owned
subsidiary
of
the
Company,
was
formed
as
a
means
of
introducing
new
products
to
the
marketplace.
Additionally,
effective
July
1,
2000,
the
Company
acquired
a
60%
ownership
position
in
Caribbean
Pacific
Natural
Products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | QGLY
is
engaged
in
the
business
of
marketing
of
health
products
such
as
cold
remedy
Cold-Eeze(R).
QGLY
also
has
a
nutrition
and
weight
management
program
called
Bodymate(TM).
For
the
six
months
ended
6/30/01,
total
revenues
rose
51%
to
$9.4
million.
Net
loss
fell
81%
to
$1.1
million.
Revenues
reflect
a
$1.3
million
settlement
fee
in
the
lawsuit
against
Gel
Tech
and
Gum
Tech
International
and
an
increase
in
Cold-Eeze
sales.
Lower
loss
reflects
decreased
advertising
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Guy Quigley, 59 Chairman,
Pres and CEO | $1.1M | $206K | Charles Phillips, 53 Exec.
VP, COO | 584K | -- | George Longo, 54 VP,
CFO | 331K | -- | Eric Kaytes, 46 VP,
CIO, Sec., Treasurer | 258K | 62K | Joseph Casey VP
of Sales and Marketing | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|